Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an investigational drug that has not been approved by the FDA for commercial distribution in the United States.
Aadi plans to continue its precision medicine approach through initiation of a registrational trial in tumor-agnostic TSC1 and TSC2 alterations.
Please check out Our Science and Pipeline for information about our work